A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex.
Antiseizure medication
Autism
Cognition
Rare disease
Refractory epilepsy
Tuberous sclerosis complex
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
14
11
2022
accepted:
25
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by mutations in the TSC1 or TSC2 gene. More than 90% of patients with TSC develop neurological and/or neuropsychiatric manifestations. The aim of the present study was to determine the developmental and cognitive long-term outcomes of pediatric TSC patients. This cross-sectional, monocenter study included pediatric TSC patients who received multidisciplinary long-term care with a last visit between 2005 and 2019. Neurological manifestations and cognitive development (BSID, K-ABC) were analyzed in relation to age and type of mutation. Thirty-five patients aged 13.5 ± 7.8 years were included in the study. Diagnosis was confirmed genetically in 65.7% of patients (TSC1, 26.1%; TSC2, 65.2%; NMI, 8.7%). Mean age at diagnosis was 1.3 ± 3.5 years; 74.3% of the patients had been diagnosed within the first year of life due to seizures (62.9%) or/and cardiac rhabdomyomas (28.6%). The most common TSC manifestations included structural brain lesions (cortical tubers, 91.4%; subependymal nodules, 82.9%), epilepsy (85.7%), and cardiac rhabdomyomas (62.9%). Mean age at seizure onset was 1.5 ± 2.3 years, with onset in 80.0% of patients within the first two years of life. Infantile spasms, which were the first seizure type in 23.3% of the patients, developed earlier (0.6 ± 0.4 years) than focal seizures (1.8 ± 2.5 years). Refractory epilepsy was present in 21 (70.0%) patients, mild or severe intellectual impairment in 66.6%, and autism spectrum disorders in 11.4%. Severe cognitive impairment (33.3%) was significantly associated with epilepsy type and age at seizure onset (p < 0.05). The results emphasized the phenotypic variability of pediatric-onset TSC and the high rate of neurological and neuropsychiatric morbidity. Early-onset refractory epilepsy was associated with impaired cognitive development. Children of all ages with TSC require multidisciplinary long-term care and individual early-intervention programs.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by mutations in the TSC1 or TSC2 gene. More than 90% of patients with TSC develop neurological and/or neuropsychiatric manifestations. The aim of the present study was to determine the developmental and cognitive long-term outcomes of pediatric TSC patients.
METHODS
METHODS
This cross-sectional, monocenter study included pediatric TSC patients who received multidisciplinary long-term care with a last visit between 2005 and 2019. Neurological manifestations and cognitive development (BSID, K-ABC) were analyzed in relation to age and type of mutation.
RESULTS
RESULTS
Thirty-five patients aged 13.5 ± 7.8 years were included in the study. Diagnosis was confirmed genetically in 65.7% of patients (TSC1, 26.1%; TSC2, 65.2%; NMI, 8.7%). Mean age at diagnosis was 1.3 ± 3.5 years; 74.3% of the patients had been diagnosed within the first year of life due to seizures (62.9%) or/and cardiac rhabdomyomas (28.6%). The most common TSC manifestations included structural brain lesions (cortical tubers, 91.4%; subependymal nodules, 82.9%), epilepsy (85.7%), and cardiac rhabdomyomas (62.9%). Mean age at seizure onset was 1.5 ± 2.3 years, with onset in 80.0% of patients within the first two years of life. Infantile spasms, which were the first seizure type in 23.3% of the patients, developed earlier (0.6 ± 0.4 years) than focal seizures (1.8 ± 2.5 years). Refractory epilepsy was present in 21 (70.0%) patients, mild or severe intellectual impairment in 66.6%, and autism spectrum disorders in 11.4%. Severe cognitive impairment (33.3%) was significantly associated with epilepsy type and age at seizure onset (p < 0.05).
CONCLUSIONS
CONCLUSIONS
The results emphasized the phenotypic variability of pediatric-onset TSC and the high rate of neurological and neuropsychiatric morbidity. Early-onset refractory epilepsy was associated with impaired cognitive development. Children of all ages with TSC require multidisciplinary long-term care and individual early-intervention programs.
Identifiants
pubmed: 37946245
doi: 10.1186/s13023-023-02959-0
pii: 10.1186/s13023-023-02959-0
pmc: PMC10637019
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349Informations de copyright
© 2023. The Author(s).
Références
Acta Neurol Scand. 2021 Jul;144(1):29-40
pubmed: 33748956
Orphanet J Rare Dis. 2018 Jul 17;13(1):117
pubmed: 30016967
Orphanet J Rare Dis. 2018 Sep 10;13(1):157
pubmed: 30201051
J Child Neurol. 2017 Dec;32(14):1092-1098
pubmed: 29129154
J Neurol Sci. 2021 Aug 15;427:117506
pubmed: 34087568
Front Neurol. 2020 Oct 16;11:582891
pubmed: 33178126
Orphanet J Rare Dis. 2020 Jan 21;15(1):23
pubmed: 31964424
Epilepsia. 2014 Jan;55(1):108-16
pubmed: 24417555
J Epilepsy Res. 2017 Jun 30;7(1):45-49
pubmed: 28775955
Orphanet J Rare Dis. 2017 Jan 5;12(1):2
pubmed: 28057044
Seizure. 2017 Dec;53:4-9
pubmed: 29078087
Epilepsia. 2015 Aug;56(8):1239-45
pubmed: 26046563
Epilepsia Open. 2019 Oct 27;4(4):581-592
pubmed: 31819914
Pediatr Neurol. 2020 Aug;109:39-46
pubmed: 32418847
Oxid Med Cell Longev. 2017;2017:9820181
pubmed: 28386314
Epilepsia. 2010 Jul;51(7):1236-41
pubmed: 20041940
J Clin Med. 2019 Jun 03;8(6):
pubmed: 31163675
Dev Med Child Neurol. 2020 Mar;62(3):322-329
pubmed: 31538337
Front Neurol. 2021 Sep 08;12:697467
pubmed: 34566842
Epilepsia. 2014 Jul;55(7):1025-9
pubmed: 24917535
Pediatr Neurol. 2021 Oct;123:43-49
pubmed: 34399109
Genet Med. 2007 Feb;9(2):88-100
pubmed: 17304050
Epilepsia. 2021 Dec;62(12):3029-3041
pubmed: 34693520
Nat Med. 2008 Aug;14(8):843-8
pubmed: 18568033
Expert Rev Clin Pharmacol. 2021 Jun;14(6):749-760
pubmed: 33792454
Am J Hum Genet. 2001 Jan;68(1):64-80
pubmed: 11112665
J Child Neurol. 2013 Apr;28(4):461-9
pubmed: 22772159
Front Pharmacol. 2022 Apr 08;13:802334
pubmed: 35462939
Eur J Paediatr Neurol. 2021 Nov;35:111-122
pubmed: 34673401
Neuropediatrics. 2018 Jun;49(3):193-199
pubmed: 29558773
Epilepsy Behav. 2017 May;70(Pt A):245-252
pubmed: 28457992
Eur J Paediatr Neurol. 2018 Sep;22(5):738-748
pubmed: 29880258
Ann Neurol. 2021 Feb;89(2):304-314
pubmed: 33180985
J Neurol Sci. 2018 Aug 15;391:104-108
pubmed: 30103955
Neurology. 2022 Mar 22;98(12):e1216-e1225
pubmed: 35101906
Epilepsia Open. 2018 Dec 21;4(1):73-84
pubmed: 30868117
Pediatr Neurol. 2021 Oct;123:50-66
pubmed: 34399110
Front Neurol. 2022 May 24;13:863826
pubmed: 35685742
Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):281-290
pubmed: 30255984
Pediatr Neurol. 2019 Jul;96:58-63
pubmed: 31005478
Nephrol Dial Transplant. 2019 Mar 1;34(3):502-508
pubmed: 29697822
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:217-240
pubmed: 31018109
Ann Clin Transl Neurol. 2017 Nov 12;4(12):877-887
pubmed: 29296616
Pediatr Neurol. 2013 Oct;49(4):255-65
pubmed: 24053983
Pediatrics. 2017 Dec;140(6):
pubmed: 29101226
Pediatr Neurol. 2010 Jul;43(1):29-34
pubmed: 20682200
Expert Rev Neurother. 2020 Feb;20(2):167-173
pubmed: 31855066
J Neurol. 2017 Jan;264(1):161-167
pubmed: 27878438
JAMA Neurol. 2021 Mar 1;78(3):285-292
pubmed: 33346789
Epilepsy Behav. 2021 Sep;122:108210
pubmed: 34311180
Epilepsy Behav. 2022 Jan;126:108431
pubmed: 34883463
Lancet Child Adolesc Health. 2018 Jul;2(7):495-504
pubmed: 30169322